JP2021528096A - エキソソーム細胞外小胞及びその使用方法 - Google Patents

エキソソーム細胞外小胞及びその使用方法 Download PDF

Info

Publication number
JP2021528096A
JP2021528096A JP2020573481A JP2020573481A JP2021528096A JP 2021528096 A JP2021528096 A JP 2021528096A JP 2020573481 A JP2020573481 A JP 2020573481A JP 2020573481 A JP2020573481 A JP 2020573481A JP 2021528096 A JP2021528096 A JP 2021528096A
Authority
JP
Japan
Prior art keywords
lnp
exosome
cells
lipid
modified rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020573481A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020002540A5 (enExample
Inventor
ハディ・ヴァラディ
レンナルト・リンドフォーシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadi Valadi
AstraZeneca AB
Original Assignee
Hadi Valadi
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadi Valadi, AstraZeneca AB filed Critical Hadi Valadi
Publication of JP2021528096A publication Critical patent/JP2021528096A/ja
Publication of JPWO2020002540A5 publication Critical patent/JPWO2020002540A5/ja
Priority to JP2024034020A priority Critical patent/JP2024081661A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020573481A 2018-06-28 2019-06-27 エキソソーム細胞外小胞及びその使用方法 Pending JP2021528096A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024034020A JP2024081661A (ja) 2018-06-28 2024-03-06 エキソソーム細胞外小胞及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691348P 2018-06-28 2018-06-28
US62/691,348 2018-06-28
PCT/EP2019/067232 WO2020002540A1 (en) 2018-06-28 2019-06-27 Exosome extracellular vesicles and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034020A Division JP2024081661A (ja) 2018-06-28 2024-03-06 エキソソーム細胞外小胞及びその使用方法

Publications (2)

Publication Number Publication Date
JP2021528096A true JP2021528096A (ja) 2021-10-21
JPWO2020002540A5 JPWO2020002540A5 (enExample) 2022-07-04

Family

ID=67139730

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573481A Pending JP2021528096A (ja) 2018-06-28 2019-06-27 エキソソーム細胞外小胞及びその使用方法
JP2024034020A Pending JP2024081661A (ja) 2018-06-28 2024-03-06 エキソソーム細胞外小胞及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024034020A Pending JP2024081661A (ja) 2018-06-28 2024-03-06 エキソソーム細胞外小胞及びその使用方法

Country Status (5)

Country Link
US (1) US12109310B2 (enExample)
EP (1) EP3813798A1 (enExample)
JP (2) JP2021528096A (enExample)
CN (1) CN112543629A (enExample)
WO (1) WO2020002540A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
KR20230167008A (ko) * 2020-08-06 2023-12-07 모더나티엑스, 인크. 지질 나노입자의 제조 방법
JP7633787B2 (ja) * 2020-09-23 2025-02-20 三洋化成工業株式会社 細胞外小胞の製造方法
US20220218622A1 (en) 2020-10-14 2022-07-14 George Mason Research Foundation, Inc. Ionizable lipids and methods of manufacture and use thereof
WO2023178500A1 (en) * 2022-03-22 2023-09-28 Beijing Theraxyte Bioscience Co. Ltd. Therapeutic vesicles and methods of processing the same
CN114848608B (zh) * 2022-05-17 2024-01-30 东南大学 一种蛋白或多肽递送载体及其制备方法与应用
CN115887758B (zh) * 2022-11-15 2024-01-26 西南交通大学 负载外泌体促进糖尿病创面修复的共聚水凝胶
CN117679354B (zh) * 2024-02-04 2024-05-28 知想(山东)医疗科技有限公司 金花茶外泌体制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010285426A (ja) * 2009-05-11 2010-12-24 National Cancer Center 核酸導入方法
JP2012524052A (ja) * 2009-04-17 2012-10-11 アイシス イノヴェイション リミテッド 遺伝物質の送達用の組成物
JP2015501844A (ja) * 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
JP2017502997A (ja) * 2014-01-21 2017-01-26 アンヤリウム バイオサイエンシーズ アーゲー ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230098713A (ko) 2009-06-10 2023-07-04 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
HRP20221536T1 (hr) 2014-06-25 2023-02-17 Acuitas Therapeutics Inc. Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
CN114642735A (zh) * 2015-01-21 2022-06-21 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
US20210290556A1 (en) * 2016-08-22 2021-09-23 Codiak Biosciences, Inc. Methods of suppressing delivery of exosomes to liver and spleen
EP3292861A1 (en) 2016-09-13 2018-03-14 Centre National De La Recherche Scientifique (Cnrs) An in vitro method for obtaining a biohybrid vector

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524052A (ja) * 2009-04-17 2012-10-11 アイシス イノヴェイション リミテッド 遺伝物質の送達用の組成物
JP2010285426A (ja) * 2009-05-11 2010-12-24 National Cancer Center 核酸導入方法
JP2015501844A (ja) * 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
JP2017502997A (ja) * 2014-01-21 2017-01-26 アンヤリウム バイオサイエンシーズ アーゲー ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NATURE COMMUNICATIONS, vol. 8: 1145, JPN6023023378, 2017, pages 1 - 15, ISSN: 0005190731 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 334, no. 17, JPN6023004527, 1996, pages 1135 - 1138, ISSN: 0005190732 *
膜（MEMBRANE）, vol. 40（5）, JPN6023045832, 2015, pages 235 - 241, ISSN: 0005190733 *

Also Published As

Publication number Publication date
WO2020002540A1 (en) 2020-01-02
CN112543629A (zh) 2021-03-23
EP3813798A1 (en) 2021-05-05
US20210315819A1 (en) 2021-10-14
JP2024081661A (ja) 2024-06-18
US12109310B2 (en) 2024-10-08

Similar Documents

Publication Publication Date Title
JP2021528096A (ja) エキソソーム細胞外小胞及びその使用方法
Maugeri et al. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells
Qu et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease
JP2025108727A (ja) 脂質ナノ粒子の生成方法
Scalzo et al. Ionizable lipid nanoparticle-mediated delivery of plasmid DNA in cardiomyocytes
JP2023138984A (ja) Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａを送達するための脂質ナノ粒子
Betker et al. Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery
US12133923B2 (en) Lipid nanoparticle compositions and uses thereof
CN110446506B (zh) 纳米脂质体-微泡缀合物及包含其的用于改善或治疗毛发脱落的组合物
CN119654166A (zh) mRNA递送方法及其组合物
WO2020262150A1 (ja) 脂質ナノ粒子
Rahman et al. Liposome-based nanomedicine therapeutics for rheumatoid arthritis
Tang et al. Nanovector assembled from natural egg yolk lipids for tumor-targeted delivery of therapeutics
Fieni et al. Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing
Huang et al. Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma
Younis et al. Harnessing the composition of lipid nanoparticles to selectively deliver mRNA to splenic immune cells for anticancer vaccination
JP2023513302A (ja) 治療的に活性な作用物質を内皮へと送達するための脂質組成物およびその使用
Fieni et al. Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival
CN118766874B (zh) 一种吸入式制剂、迭代优化流程及其应用
US20230165795A1 (en) Liposomes for targeting tumor-associated macrophages
US20240316165A1 (en) Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
JP2023039115A (ja) 物質送達キャリア及び組成物
US12364773B2 (en) Lipid nanoparticle compositions and uses thereof
CN117582512B (zh) 金属-多酚复合物颗粒及其制备方法和应用
CN120437322A (zh) 靶向载体、靶向药物及制备方法与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240423

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240614

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250217